摘要
目的分析血清癌胚抗原(CEA)、糖类抗原(CA)15-3、细胞角蛋白19片段(CYFRA21-1)、环氧化酶-2(COX-2)联合检测乳腺癌的效果。方法将2019年4月至2022年4月在我院诊治的110例乳腺癌患者纳入观察组,将同期在我院诊治的103例良性乳腺疾病患者纳入对照组,另把同时段在我院体检的95例健康人群纳入健康组。采集所有研究对象的静脉血,检测三组的各项肿瘤标志物的差异;另绘制受试者工作曲线(ROC),分析CEA、CA15-3、CYFRA21-l、COX-2单独或联合诊断乳腺癌的效能。结果观察组CEA、CA15-3、CYFRA21-l、COX-2水平高于对照组与健康组,差异有统计学意义(P<0.05);ROC结果显示:CEA、CA15-3、CYFRA21-l、COX-2四者联合检测的曲线下面积(AUC)为0.907(95%CI 0.860~0.954),高于四者单独检测的0.802(95%CI 0.741~0.863)、0.828(95%CI 0.768~0.887)、0.826(95%CI 0.767~0.885)、0.803(95%CI 0.738~0.868)。结论CEA、CA15-3、CYFRA21-l、COX-2四者在乳腺癌患者机体内呈高表达,几者联合可有效诊断出乳腺癌,临床运用价值较高,值得推行。
Objectives To analyze the effects of combined serum carcinoembryonic antigen(CEA),carbohydrate antigen(CA)15-3,cytokeratin 19 fragment(CYFRA21-1)and cyclooxygenase-2(COX-2)in the detection of breast cancer.Methods A total of 110 patients with breast cancer treated in our hospital from April 2019 to April 2022 were included in the observation group,103 patients with benign breast disease treated in our hospital during the same period were included in the control group,and 95 healthy people who underwent physical examination in our hospital during the same period were included in the healthy group.Venous blood of all subjects was collected to detect the differences of tumor markers among the three groups.In addition,the receiver operating curve(ROC)was drawnto analyze the efficacy of CEA,CA15-3,CYFRA21-l,and COX-2 alone or in combination in the diagnosis of breast cancer.Result sThe levels of CEA,CA15-3,CYFRA21-l,and COX-2 in the observation group were significantly higher than those in the control group and the healthy group(P<0.05).The results of ROC showed that the area under the curve(AUC)of combined detection of CEA,CA15-3,CYFRA21-l and COX-2 was 0.907(95%CI 0.860~0.954),which washigher than 0.802(95%CI 0.741~0.863),0.828(95%CI 0.768~0.887),0.826(95%CI 0.767~0.885),0.803(95%CI 0.738~0.868)of the four individual detections.Conclusions CEA,CA15-3,CYFRA21-l and COX-2 are highly expressed in breast cancer patients,and the combination of the four can effectively diagnose breast cancer,which is of high clinical application value and is worth promoting.
作者
陈桂
CHEN GUI(Department of Laboratory,The Third People's Hospital of Xinghua city,Xinghua 225700 Jiangsu,China)
出处
《现代诊断与治疗》
CAS
2023年第7期963-965,共3页
Modern Diagnosis and Treatment
关键词
乳腺癌
癌胚抗原
糖类抗原
细胞角蛋白19片段
肿瘤标志物
Breast cancer
Carcinoembryonic antigen,Carbohydrate antigen
Cytokeratin 19 fragment
Tumor markers
